Pilot Study of Interleukin-2 and Lymphokine-Activated Killer Cells Combined With Immunomodulatory Doses of Chemotherapy and Sequenced With Interferon Alfa-2a in Patients With Metastatic Melanoma and Renal Cell Carcinoma

Sznol, Mario; Clark, Jeffrey W.; Smith, John W.; Steis, Ronald G.; Urba, Walter J.; Rubinstein, Larry; VanderMolen, Louis A.; Janik, John E.; Sharfman, William H.; Fenton, R. G.; Creekmore, Stephen P.; Kremers, Peter W.; Conlon, Kevin C.; Hersey, Jean; Beveridge, Joy; Longo, Dan L.

doi:10.1093/jnci/84.12.929

Cited by 33 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is a statistical literature analysis based upon 80 publications of treatment of RCCa with IL-2 alone, in combination with other agents, or with LAK cells [12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92]. Reports were identified from citations in recent complete publications and from a Medline search through July 1999.…”

Section: Methodsmentioning

confidence: 99%

A Literature Analysis of Prognostic Factors for Response and Quality of Response of Patients with Renal Cell Carcinoma to Interleukin-2-Based Therapy

Elias

Hunt²

2001

Oncology

View full text Add to dashboard Cite

Objective: To characterize prognostic factors for response of advanced renal cell carcinoma to interleukin-2-based regimens. Patients and Methods: Data compiled from 80 published series were examined for associations between patient characteristics and outcomes. Results: Response rates were highest in trials utilizing interleukin-2 combinations. Longer median survivals were associated with high percentages of patients with nephrectomy, good performance status, with publication year, response rates, and inversely with median ages. Associations of performance status and prior nephrectomy with response rates were detected in trials with individual patient details. The response rate was higher for patients older than the median age of patients entering each trial, and also higher for males. Among responders, attainment of complete response was associated with fewer sites of involvement. Pooled response duration of patients reported to have complete responses exhibited durability, but no correlation with prognostic factors. Selection factors may have influenced apparent differences between types of regimens. We confirm the potential for durable remissions from interleukin-2-based regimens.

show abstract

Section: Methodsmentioning

confidence: 99%

A Literature Analysis of Prognostic Factors for Response and Quality of Response of Patients with Renal Cell Carcinoma to Interleukin-2-Based Therapy

Elias

Hunt²

2001

Oncology

View full text Add to dashboard Cite

show abstract

“…Side effects, therefore, are related to the administered dose of IL‐2. Response rates for the treatment of metastatic renal cell carcinoma range from nine to 33 percent (average 23.5 percent) and are summarized in Table 4 91,107–113 . A single, randomized study has compared the use of IL‐2 alone with combined IL‐2/LAK treatment.…”

Section: Management Of Metastatic Diseasementioning

confidence: 99%

Current management of renal cell carcinoma

Sokoloff

deKernion

Figlin

et al. 1996

CA: A Cancer Journal for Clinicians

View full text Add to dashboard Cite

Biologic therapy of melanoma with cytokines and lymphocytes

Bear

Hamad

Kostuchenko

1996

Semin. Surg. Oncol.

View full text Add to dashboard Cite

Melanoma has a somewhat unpredictable behavior, and spontaneous regressions do occasionally occur. Many have surmised that these are the result of immunologic attack by the host. Immunologic treatment has been more successful for melanoma than for most other neoplasms, even with relatively crude therapies, such as bacterial products. With the availability of recombinant cytokines, immunotherapy for melanoma has entered a new era. Interleukin‐2 (IL‐2), which acts entirely through immunologic mechanisms, has been tested extensively, either alone, in combination with other cytokines, or with adoptive cellular therapy. Alone, it has only modest antitumor activity, even at high doses. Its utility may be greater when combined with immunocompetent cells, especially tumor‐sensitized T lymphocytes, in adoptive immunotherapy. On the other hand, nonspecific lymphokine‐activated killer (LAK) cells do not appear to add significantly to the efficacy of IL‐2 alone. Interferon‐γ (IFN‐γ) also has had fairly limited activity in the advanced disease setting, but, on the basis of a recently completed randomized trial, has arguably become the “standard of care” in the adjuvant setting for patients with high‐risk melanoma, particularly node‐positive patients. A number of regimens combining IL‐2, IFN‐γ, and chemotherapeutic agents have yielded striking response rates in small trials and await confirmation in larger studies. With better delineation of the host immune response and definition of relevant tumor antigens, we can look forward to exciting results with combinations of vaccines, cytokines, and adoptive cellular approaches, particularly in patients with micrometastatic disease. © 1996 Wiley‐Liss, Inc.

show abstract

Pilot Study of Interleukin-2 and Lymphokine-Activated Killer Cells Combined With Immunomodulatory Doses of Chemotherapy and Sequenced With Interferon Alfa-2a in Patients With Metastatic Melanoma and Renal Cell Carcinoma

Cited by 33 publications

References 0 publications

A Literature Analysis of Prognostic Factors for Response and Quality of Response of Patients with Renal Cell Carcinoma to Interleukin-2-Based Therapy

A Literature Analysis of Prognostic Factors for Response and Quality of Response of Patients with Renal Cell Carcinoma to Interleukin-2-Based Therapy

Current management of renal cell carcinoma

Biologic therapy of melanoma with cytokines and lymphocytes

Contact Info

Product

Resources

About